RxDoctor Payments Data

Nathan Rudometkin, MD

Retina Specialist · Laguna Woods, CANPI 1225128994

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.1% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $669, more than ten times the $22 reported in 2021. That places this record below the midpoint for retina specialist clinicians in CA, where the typical reported total is $3,667.

$1,193in general payments, 2019–2025

Across 47 payments — averaging $25.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$275
  • Astellas Pharma US Inc$230
  • Regeneron Healthcare Solutions, Inc.$215
  • AbbVie$147
  • Apellis Pharmaceuticals, Inc.$128
  • Amgen$40
  • plus $158 from 5 others

What the payments were for

  • Food & beverage$1,15997%
  • Entertainment$343%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,193 in reported general payments places this provider in the 20th percentile of 187 retina specialist providers in California.

See all retina specialist providers in California →

Medicare billing

Part B allowed, 2024
$787,041
Medicare patients
413
Services billed
6,767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate188$7,476
RhopressaNetarsudil Mesylate14$5,231
Cyclosporine18$5,219
Ketorolac Tromethamine47$890
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat48$872
Ofloxacin65$871
Latanoprost83$722
Brimonidine Tartrate42$638
Dorzolamide Hcl22$294
Timolol Maleate20$231
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha14$146
Ciprofloxacin Hcl11$105

Paid to pharmacies, not to this prescriber.

Other retina specialist in Laguna Woods

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →